The impact of choice of muscle relaxant on postoperative recovery time: A retrospective study

Anesthesia and Analgesia

Volumn 85, Issue 3, 1997, Pages 476-482

  Ballantyne, Jane C ^a   Chang, YuChiao ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRACURIUM; CURARE; LONG ACTING DRUG; MIVACURIUM; MUSCLE RELAXANT AGENT; PANCURONIUM; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; VECURONIUM;

ADOLESCENT; ADULT; AGED; ANESTHETIC RECOVERY; ARTICLE; CHILD; CONTROLLED STUDY; DRUG ACTIVITY; DRUG COST; HOSPITAL COST; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROMUSCULAR BLOCKING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANESTHESIA RECOVERY PERIOD; ANESTHESIA, GENERAL; ATRACURIUM; CHILD; CHILD, PRESCHOOL; COST SAVINGS; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; INFANT; ISOQUINOLINES; MALE; MIDDLE AGED; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PANCURONIUM; RECOVERY ROOM; RETROSPECTIVE STUDIES; TUBOCURARINE; VECURONIUM BROMIDE;

EID: 0030828897     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199709000-00002     Document Type: Article

References (54)

1. Becker KE, Carrithers J. Cost-effective anesthesia. Curr Opin Anaesthesiol 1994;7:477-80.
2. Lethbridge JR, Walker JS. Cost of anesthetic drugs and clinical budgeting. BMJ 1986;293:1587-8.
3. Rathmell JP, Brooker RF, Prielipp RC, et al. Hemodynamic and pharmacodynamic comparison of doxacurium and pipecuronium with pancuronium during induction of cardiac anesthesia: does the benefit justify the cost? Anesth Analg 1993;76:513-9.
4. Johnstone RE, Martinec CL. Costs of anesthesia. Anesth Analg 1993;76:840-8.
5. Bulpitt CJ, Fletcher AE. Measuring costs and financial benefit in randomized controlled trials. Am Heart J 1990;119:766-71.
6. Cohen MM, Ducan PG, Tweed WA, et al. The Canadian four-center study of anesthetic outcomes. I. Description of methods and populations. Can J Anaesth 1992;39:420-9.
7. Gold B, Kitz D, Lecky JG, et al. Unanticipated admission to the hospital following ambulatory surgery. JAMA 1989;262: 3008-10.
8. White PF, Watcha MF. Are new drugs cost-effective for patients undergoing ambulatory surgery? Anesthesiology 1993;78:2-5.
9. Andersen BN, Madsen JV, Schurizek BA, et al. Residual curarization: a comparative study of atracurium and pancuronium. Acta Anaesthesiol Scand 1988;32:79-81.
10. Bevan DR, Smith CE, Donati F. Post-operative neuromuscular blockade: a comparison between atracurium, vecuronium and pancuronium. Anesthesiology 1988;69:272-6.
11. Brull SJ, Ehrenwerth J, Connelly NR, et al. Assessment of residual curarization using low-current stimulation. Can J Anaesth 1991;38:164-8.
12. Fahey MR, Morris RB, Miller RD, et al. Clinical pharmacology of ORG NC 45 (Norcuron). Anesthesiology 1981;55:6-11.
13. Kopman AF. Recovery times following edrophonium and neostigmine reversal of pancuronium, atracurium, and vecuronium steady-state infusions. Anesthesiology 1986;65:572-8.
14. Kopman AF, Ng J, Zank LM, et al. Residual postoperative paralysis: pancuronium versus mivacurium - does it matter? Anesthesiology 1996;85:1253-9.
15. Larijani GE, Gratz I, Minassian SS, et al. Comparative evaluation of the neuromuscular and cardiovascular effects of pipecuronium, pancuronium, atracurium and vecuronium under isoflurane anesthesia. Pharmacotherapy 1992;12:278-82.
16. Power SJ, Jones RM. Reversal of profound paralysis: use of large doses of edrophonium to antiagonize vecuronium and pancuronium induced neuromuscular blockade. Acta Anaesthesiol Scand 1989;33:478-81.
17. Sanfilippo M, Vilardi V, Fierro G, et al. Neostigmine and edrophonium as antagonists of atracurium and pancuronium. Acta Anaesthesiol Scand 1988;32:437-40.
18. Beemer GH, Rozental P. Post-operative neuromuscular function. Anaesth Intensive Care 1986;14:41-5.
19. Harrison GG. Death attributable to anaesthesia: a 10 year survey (1967-76). Br J Anaesth 1978;50:1041.
20. Lubarsky DA, Glass PSA, Ginsberg B, et al. The successful implementation of pharmaceutical practice guidelines. Anesthesiology 1997;86:1145-60.
21. Viby-Mogensen J, Jorgensen BC, Ording H. Residual curarization in the recovery room. Anesthesiology 1979;50:539-41.
22. Bevan DR, Bevan JC. Residual postoperative paralysis: yes, it does matter [letter]. Anesthesiology 1997;86:1215-6.
23. Lebowitz PW, Ramsey FW, Savarese JJ, et al. Potentiation of neuromuscular blockade in man produced by combinations of pancuronium and metocurine or pancuronium and d-tubocurarine. Anesth Analg 1980;59:604-9.
24. Draper NR, Smith H. Applied regression analysis. London: John Wiley & Sons, 1981.
25. Donati F. Cost-benefit analysis of neuromuscular blocking agents. Can J Anaesth 1994;41:R3-7.
26. Bevan DR, Kahwaji R, Arsermino JM, et al. Residual block after mivacurium with or without edrophonium reversal in adults and children. Anesthesiology 1996;84:362-7.
27. Shorten GD, Merk H, Sieber T. Perioperative train-of-four monitoring and residual curarization. Can J Anaesth 1995;42:711-5.
28. Ali HH, Wilson RS, Savarerse JJ, et al. The effect of d-tubocurarine on indirectly elicited train-of-four muscle response and respiratory measurements in humans. Br J Anaesth 1975;47:570-4.
29. Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of resideual paralysis in awake volunteers. Anesthesiology 1997;86:765-71.
30. Kopman AF, Mallhi MU, Justo MD, et al. Antagonism of mivacurium-induced neuromuscular blockade in humans: edrophonium dose requirements at threshold train-of-four count of 4. Anesthesiology 1988;69:272-6.
31. Viby-Mogensen H, Jensen NH, Engbaek J, et al. Tactile and visual evaluation of the response to train-of-four stimulation. Anesthesiology 1985;63:440-3.
32. Baraka A. The influence of carbon dioxide on the neuromuscular block caused by tubocararine in the human subject. Br J Anaesth 1964;36:272-8.
33. Maclagen J. Competitive neuromuscular blocking drugs. In: Zaimis E, ed. Neuromuscular junction. Berlin: Springer-Verlag, 1976:421.
34. Miller RD. The effect of acid-base balance on neostigmine antagonism of d-tubocurarine-induced neuromuscular blockade. Anesthesiology 1975;42:377-83.
35. Miller RD. Acid-base balance and neostigmine antagonism of pancuronium neuromuscular blockade. Br J Anaesth 1978;50: 317-24.
36. Eriksson LI, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology 1993;78:693-9.
37. Donati F, Meistelman C, Plaud B. Vecuronium neuromuscular blockade at the adductor muscles of the larynx and the adductor pollicis. Anesthesiology 1991;74:833-9.
38. Eriksson LI. Videographical computerized manometry in assessment of pharyngeal function in partially paralyzed humans [abstract]. Anesthesiology 1995;83:A886.
39. Pavlin EG, Holle RH, Schoene RB. Recovery of airway protection compared with ventilation in humans after paralysis with curare. Anesthesiology 1989;70:381-5.
40. Waud BE, Waud DR. The margin of safety of neuromuscular transmission. Anesthesiology 1972;37:417-22.
41. Fisher DM, Macario A. Economics of anesthesia care [editorial]. Anesthesiology 1997;86:1018-9.
42. Selvin S. Statistical analysis of epidemiological data. Oxford, UK: Oxford University Press, 1991:36-7.
43. Bartkowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine and edrophonium. Anesth Analg 1987;66:597-8.
44. Kopman AF. Antagonism of profound neuromuscular blockade. Probl Anesth 1989;3:405-20.
45. Savarese JJ. Clinical practice with the new relaxants: fine tuning the medical and economic aspects of relaxation. Anesth Analg 1996;82(Suppl):114-120.
46. Watcha MF. Economics of anesthetic practice. Anesthesiology 1997;86:1170-96.
47. Dexter F, Tinker JH. Analysis of strategies to decrease postanesthesia care unit costs. Anesthesiology 1995;82:94-101.
48. Souetre EJ, Qing W, Hardens M. Methodological approaches to pharmaco-economics. Fundam Clin Pharmacol 1994;8:101-7.
49. Dexter F, Macario A. Applications of information systems to operating room scheduling [editorial]. Anesthesiology 1996;85: 1232-4.
50. Macario A, Vitez TS, Dunn B, et al. Where are the costs in perioperative care? Analysis of hospital costs and charges for inpatient surgical care. Anesthesiology 1995;83:1138-44.
51. Bevan DR. Anaesthesia pharmacoeconomics. Can J Anaesth 1993;40:693-5.
52. DeMonaco HJ, Shah AS. Economic considerations in the use of neuromuscular blocking drugs. J Clin Anesth 1994;6:383-7.
53. Kapur PA. Pharmacy acquisition costs: responsible choice versus overutilization of costly pharmaceuticals [editorial]. Anesth Analg 1994;78:617-8.
54. Orkin FK. Meaningful cost reduction: penny wise, pound foolish [editorial]. Anesthesiology 1995;83:1135-7.